A real-world analysis of AbbVie’s Mavyret (glecaprevir/pibrentasvir) found the hepatitis C virus (HCV) treatment was highly effective and well tolerated, MedPage Today reports.

Researchers conducted a retrospective longitudinal study of people with hep C starting Mavyret at 30 clinics in Italy. The study looked at the traditional indicator of whether someone has been cured of hep C, a sustained virologic response 12 weeks after completing therapy (SVR12), and also determined the proportion of those who had achieved an SVR four weeks after completing therapy (SVR4). Someone with an SVR4 stands an excellent chance of maintaining an undetectable hep C viral load for another eight weeks and then achieving an SVR12.

Findings were presented at the 52nd International Liver Congress in Paris.

Between October 2017 and January 2018, a total of 723 people were treated with Mavyret, 639 of them for eight weeks and 84 for 12 to 16 weeks. About 90 percent of those treated for eight weeks had mild or no fibrosis.

Of the 347 individuals who completed treatment and had made it to the four-week posttreatment mark, 346 (99.7 percent) had achieved an SVR4. And of the 49 people who had made it to the 12-week posttreatment mark, 48 (98 percent) had achieved an SVR12. The respective corresponding rates were 99.7 percent and 97.7 percent among those treated for eight weeks and 100 percent and 100 percent among those treated for 12 to 16 weeks. One person in the eight-week treatment group experienced a viral relapse.

Of all those who received Mavyret, 6 percent of those in the eight-week treatment group and 13 percent of those in the 12- to 16-week treatment group experienced any adverse health events. A respective one and three people in each treatment group experienced adverse health events that led them to stop treatment. One person died in the shorter treatment group, and two people died in the longer treatment group.

To read the MedPage Today article, click here.